INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
26/10/2023
Voltar para busca
Dado oficial do USPTO
SAGA DIAGNOSTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SAGA DIAGNOSTICS
ST13
US500000079325831Classe
5, 42, 44
Pedido
79325831
Registro
6920300
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
26/10/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
23/06/2021
Data de registro
13/12/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/12/2022
Última transação
24/02/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
SE
Examinador
KAPLAN, VALERIE
Unidade examinadora
L70
Localização atual
TMEG LAW OFFICE 107
Titulares e representantes
Titulares
SAGA Diagnostics AB
Representantes
Sarah J. Schneider Sheridan Ross P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Diagnostic preparations and materials *not including glucose measurement testsovulation testsdrug testshuman chorionic gonadotropin (hCG) tests or HemoActives sold in pharmacies to individual customers * for medical purposes; biochemical preparations for the treatment of cancer; biological preparations for the treatment of cancer; chemical preparations for the treatment of cancer; chemical preparations for veterinary purposesspecifically for the treatment of cancer; nucleic acid sequences for medical and veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; reagents for medical use
Classe 42
Analytical medical laboratory services; blood analysis services; blood analysis services for scientific research purposes; consultancy in the field of scientific research; contract research services relating to molecular sciences; design and development of medical technology; laboratory services namely DNA testing services to determine paternity; genetic scientific research; laboratory analysis in the field of bacteriology; laboratory research in the field of gene expression; medical laboratory services; laboratory services for analytical testing; laboratory testing in the field of genetics and genetic engineering; provision of information relating to scientific research; research and development in the field of biotechnology; research laboratories in the pharmaceutical and biotechnology fields; scientific laboratory services; scientific research; scientific research and analysis in the field of genetics and genetic engineering; scientific research for medical purposes; scientific research conducted using databases; scientific servicesnamely scientific laboratory services; scientific testing services in the field of genetics and genetic engineering; medical and pharmacological research services
Classe 44
Human healthcare services; medical services; genetic counseling; genetic testing of animals for diagnostic or treatment purposes; health care services offered through a network of health care providers on a contract basis; cancer screening services; laboratory analysis services relating to the treatment of persons provided by medical laboratories; medical and healthcare clinics; medical and healthcare services; medical servicesnamely monitoring of patients; pathology servicesanalysis servicesdiagnostic services and monitoring services for studying diseases
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
24/10/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/10/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/04/2023
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
04/04/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/04/2023
FIMP
FINAL DISPOSITION PROCESSED
31/03/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/03/2023
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
27/02/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/02/2023
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
24/02/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/12/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
15/12/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
13/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
13/12/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
10/12/2022
GPNX
NOTIFICATION PROCESSED BY IB
27/09/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/09/2022
PUBO
PUBLISHED FOR OPPOSITION
27/09/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/09/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/09/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/09/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/08/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/08/2022
RFNT
REFUSAL PROCESSED BY IB
25/05/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/05/2022
RFRR
REFUSAL PROCESSED BY MPU
01/05/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/03/2022
CNRT
NON-FINAL ACTION WRITTEN
18/03/2022
DOCK
ASSIGNED TO EXAMINER
15/03/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/01/2022
MAFR
APPLICATION FILING RECEIPT MAILED
23/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SAGA DIAGNOSTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.